[Form 4] Global Medical REIT Inc. Insider Trading Activity

Rhea-AI Filing Summary

Global Medical REIT (NYSE:GMRE) Form 4 discloses that newly appointed CEO and President Mark Okey Decker Jr. purchased 160,000 common shares on 24-25 June 2025 at a weighted average price of about $6.52, committing roughly $1.0 million of personal capital. Following the transactions, he directly owns 160,000 shares.

On 23 June 2025 he also received 158,730 Long-Term Incentive Plan (LTIP) units, exchangeable one-for-one for common stock after vesting on the third anniversary of grant.

• Transaction code: P (open-market purchases)
• Ownership form: Direct
• No Rule 10b5-1 plan indicated

The >$1 million insider buy by the CEO is a potentially positive signal of management confidence and tighter alignment with shareholder interests.

Positive

• $1.0 million open-market purchase of 160,000 shares by CEO, indicating confidence
• 158,730 LTIP units grant further aligns executive with shareholder value

Negative

• None.

Insights

Insider Transactions Analyst

CEO invests $1M+; bullish insider signal.

The open-market purchase of 160,000 shares at ~$6.52 represents a meaningful cash outlay for a newly installed chief executive. Because the transaction was voluntary (code P) and outside a 10b5-1 plan, it suggests a discretionary view that the stock is undervalued. Coupled with the simultaneous award of 158,730 LTIP units, the CEO now has material upside exposure to future share appreciation, sharply aligning incentives with common shareholders. The size comfortably exceeds the $1 million materiality threshold, and the purchase price floors near recent market levels, limiting downside-signal risk. Overall, the filing reads as a constructive indicator for sentiment, though investors should monitor post-vest dilution from LTIP conversion.

Portfolio Manager

Purchase positives tempered by future dilution risk.

The $1 million buy is encouraging, but the 158,730 LTIP units, while standard, will eventually add to share count once vested and converted. Unless future earnings growth offsets this dilution, the benefit of today’s alignment could fade. The grant is time-based with no disclosed performance hurdles, limiting its motivational punch. Net impact: modestly constructive yet not transformational.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Decker Mark Okey Jr

(Last) (First) (Middle)

7373 WISCONSIN AVENUE, SUITE 800

(Street)

BETHESDA MD 20814

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Global Medical REIT Inc. [ GMRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2025		P		100,000	A	$6.527(1)	100,000	D
Common Stock	06/24/2025		P		2,668	A	$6.3695(2)	102,668	D
Common Stock	06/25/2025		P		30,757	A	$6.4656(3)	133,425	D
Common Stock	06/25/2025		P		8,072	A	$6.5635(4)	141,497	D
Common Stock	06/25/2025		P		18,503	A	$6.539(5)	160,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
LTIP Unit (Right to Buy)(6)	(7)	06/23/2025		A		158,730		(7)	(7)	Common Stock	158,730	$0	158,730	D

Explanation of Responses:

1. This is the weighted average purchase price. Shares were purchased in multiple transactions at prices ranging from $6.31 to $6.60, inclusive. The amount reflected has been rounded to four decimal points. The reporting person undertakes to provide to Global Medical REIT Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4.

2. This is the weighted average purchase price. Shares were purchased in multiple transactions at prices ranging from $6.32 to $6.40, inclusive. The amount reflected has been rounded to four decimal points.

3. This is the weighted average purchase price. Shares were purchased in multiple transactions at prices ranging from $6.44 to $6.505, inclusive. The amount reflected has been rounded to four decimal points.

4. This is the weighted average purchase price. Shares were purchased in multiple transactions at prices ranging from $6.555 to $6.585, inclusive. The amount reflected has been rounded to four decimal points.

5. This is the weighted average purchase price. Shares were purchased in multiple transactions at prices ranging from $6.4925 to $6.615, inclusive. The amount reflected has been rounded to four decimal points.

6. Represents units of limited partnership interests ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer, that were granted to the Reporting Person under the Issuer's 2016 Equity Incentive Plan (as amended from time to time) in connection with the Reporting Person's appointment as President and Chief Executive Officer, effective June 23, 2025 (the "grant date"). All of the LTIP Units vest on the third anniversary of the grant date.

7. As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.

	/s/ Jamie Barber, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did [[**GMRE**]]'s CEO buy on 24-25 June 2025?

The filing reports 160,000 common shares purchased over those two days.

What was the weighted average purchase price for [[**GMRE**]] shares?

Weighted averages were $6.527, $6.3695, $6.4656, $6.5635 and $6.539, equating to roughly $6.52 overall.

How much capital did the CEO invest in [[**GMRE**]] stock?

At about $6.52 per share for 160,000 shares, the cash outlay was roughly $1.0 million.

What equity award did the CEO receive according to the Form 4?

He was granted 158,730 LTIP units that vest on 23 June 2028 and are exchangeable 1-for-1 into common stock.

Does the Form 4 indicate a Rule 10b5-1 trading plan for [[**GMRE**]]?

No. The checkbox for a Rule 10b5-1(c) plan was not marked, indicating discretionary purchases.